Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Meningococcal B Disease”

102 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 102 results

Post-approval studies (Phase 4)Study completedNCT03274102
What this trial is testing

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Who this might be right for
Hand, Foot and Mouth Disease
Sinovac Biotech Co., Ltd 780
Testing effectiveness (Phase 2)Study completedNCT02534935
What this trial is testing

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Who this might be right for
Meningococcal B Disease
Pfizer 396
Testing effectiveness (Phase 2)Study completedNCT00808028
What this trial is testing

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Who this might be right for
Meningitis, Meningococcal
Pfizer 538
Post-approval studies (Phase 4)Study completedNCT02569632
What this trial is testing

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Who this might be right for
Meningococcal Infections
UCSF Benioff Children's Hospital Oakland 18
Testing effectiveness (Phase 2)Study completedNCT05294588
What this trial is testing

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Who this might be right for
Gonorrhea Male
University of North Carolina, Chapel Hill 65
Large-scale testing (Phase 3)Study completedNCT01717638
What this trial is testing

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 805
Large-scale testing (Phase 3)Study completedNCT02106390
What this trial is testing

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 750
Early research (Phase 1)Study completedNCT00248833
What this trial is testing

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Who this might be right for
Meningitis, Meningococcal, Serogroup B
U.S. Army Medical Research and Development Command 34
Large-scale testing (Phase 3)Active Not RecruitingNCT04415424
What this trial is testing

Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men

Who this might be right for
Neisseria Gonorrheae Infection
Kirby Institute 650
Not applicableStudy completedNCT01452438
What this trial is testing

Safety Surveillance of MenACWY-CRM Vaccine in Children

Who this might be right for
Meningococcal Disease
Novartis Vaccines 393
Testing effectiveness (Phase 2)Study completedNCT00937521
What this trial is testing

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Who this might be right for
Meningococcal MeningitisMeningococcal Infections
Novartis Vaccines 1,507
Large-scale testing (Phase 3)Study completedNCT00661713
What this trial is testing

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Who this might be right for
Meningococcal Disease
Novartis Vaccines 1,631
Testing effectiveness (Phase 2)Study completedNCT04886154
What this trial is testing

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 1,440
Post-approval studies (Phase 4)Study completedNCT01659996
What this trial is testing

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

Who this might be right for
MeningitisMeningococcal InfectionDiphtheria+3 more
Sanofi Pasteur, a Sanofi Company 1,394
Post-approval studies (Phase 4)Study completedNCT03125616
What this trial is testing

Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B

Who this might be right for
PrematurityVaccinationMeningococcal Disease
St George's, University of London 136
Large-scale testing (Phase 3)Study completedNCT00291343
What this trial is testing

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 296
Large-scale testing (Phase 3)Study completedNCT03621670
What this trial is testing

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 1,196
Post-approval studies (Phase 4)UnknownNCT03682939
What this trial is testing

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population

Who this might be right for
HivMeningitis, MeningococcalHIV Infections
St George's, University of London 55
Post-approval studies (Phase 4)Looking for participantsNCT07252804
What this trial is testing

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Who this might be right for
Autoimmune Rheumatologic Disease
University of Sao Paulo General Hospital 263
Large-scale testing (Phase 3)Study completedNCT00944034
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 1,588
Next Page